An earlier uncontrolled phase II trial indicated preferential benefit from cilengitide in newly diagnosed glioblastoma patients with, as opposed to without, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation [10]. This evidence concerns the gene MGMT and glioblastoma.